[go: up one dir, main page]

CA2445125A1 - Micro-emulsions en tant que precurseurs de nanoparticules solides - Google Patents

Micro-emulsions en tant que precurseurs de nanoparticules solides Download PDF

Info

Publication number
CA2445125A1
CA2445125A1 CA002445125A CA2445125A CA2445125A1 CA 2445125 A1 CA2445125 A1 CA 2445125A1 CA 002445125 A CA002445125 A CA 002445125A CA 2445125 A CA2445125 A CA 2445125A CA 2445125 A1 CA2445125 A1 CA 2445125A1
Authority
CA
Canada
Prior art keywords
nanoparticle
microemulsion
nanoparticles
molecule
pdna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002445125A
Other languages
English (en)
Inventor
Russell John Mumper
Michael Jay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Kentucky Research Foundation
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/812,884 external-priority patent/US7153525B1/en
Application filed by Individual filed Critical Individual
Publication of CA2445125A1 publication Critical patent/CA2445125A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne la préparation de nouvelles micro-émulsions utilisables en tant que précurseurs de nanoparticules solides. Les micro-émulsions précurseurs sont constituées soit de micro-émulsions d'alcool dans du fluorocarbure, des micro-émulsions d'hydrocarbure liquide dans du fluorocarbure, ou des micro-émulsions d'hydrocarbure liquide dans l'eau. Les nanoparticules ainsi formées présentent des diamètres inférieurs à 200 nanomètres et peuvent servir à l'encapsulation de divers matériaux comprenant des médicaments, des aimants, et des capteurs. Les nanoparticules solides peuvent servir à cibler diverses cellules dans le corps par l'inclusion d'un ligand de ciblage spécifique de cellules. L'invention concerne également des procédés de préparation de nouvelles micro-émulsions précurseurs et des procédés de cuisson de nanoparticules.
CA002445125A 2001-03-21 2002-03-21 Micro-emulsions en tant que precurseurs de nanoparticules solides Abandoned CA2445125A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/812,884 US7153525B1 (en) 2000-03-22 2001-03-21 Microemulsions as precursors to solid nanoparticles
US09/812,884 2001-03-21
PCT/US2002/008936 WO2002076441A1 (fr) 2001-03-21 2002-03-21 Micro-emulsions en tant que precurseurs de nanoparticules solides

Publications (1)

Publication Number Publication Date
CA2445125A1 true CA2445125A1 (fr) 2002-10-03

Family

ID=25210874

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002445125A Abandoned CA2445125A1 (fr) 2001-03-21 2002-03-21 Micro-emulsions en tant que precurseurs de nanoparticules solides

Country Status (3)

Country Link
EP (1) EP1379227A4 (fr)
CA (1) CA2445125A1 (fr)
WO (1) WO2002076441A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763663B2 (en) 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US7438903B2 (en) * 2003-06-06 2008-10-21 Nbty, Inc. Methods and compositions that enhance bioavailability of coenzyme-Q10
AU2003903296A0 (en) * 2003-06-30 2003-07-10 Raustech Pty Ltd Chemical compositions of matter
US7803366B2 (en) 2004-05-07 2010-09-28 Nbty, Inc. Methods and compositions that enhance bioavailability of coenzyme-Q10
EP1598060A1 (fr) * 2004-05-18 2005-11-23 Nestec S.A. Émulsion huile dans eau pour livraison
EP1597973A1 (fr) * 2004-05-18 2005-11-23 Nestec S.A. Emulsion d'huile dans l'eau pour livraison
JP2008512350A (ja) * 2004-07-01 2008-04-24 イェール ユニバーシティ 標的化され、そして高密度で薬物が負荷されるポリマー性物質
EP1661559A1 (fr) * 2004-11-25 2006-05-31 NanoDel Technologies GmbH Systéme de délivrance produit par un procédé de miniémulsion
CA2579957A1 (fr) * 2004-09-14 2006-03-23 Nanodel Technologies Gmbh Vehicule d'administration de medicaments contenant des nanoparticules
WO2006056362A2 (fr) * 2004-11-25 2006-06-01 Nanodel Technologies Gmbh Vehicule d'administration fabrique au moyen du procede de miniemulsion
PL1957041T3 (pl) 2005-11-22 2011-02-28 Nestec Sa Emulsja olej-w-wodzie i jej zastosowanie dla nadania funkcji
AU2006316501A1 (en) * 2005-11-22 2007-05-31 Nestec S.A. Easily dispersible lipidic phase
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
EP1815851A1 (fr) * 2006-02-03 2007-08-08 NanoDel Technologies GmbH Nanoparticules pour l'administration de médicaments
GB0623838D0 (en) * 2006-11-29 2007-01-10 Malvern Cosmeceutics Ltd Novel compositions
US8889117B2 (en) 2007-02-15 2014-11-18 Yale University Modular nanoparticles for adaptable vaccines
WO2008121926A1 (fr) 2007-03-30 2008-10-09 Particle Sciences, Inc. Formulations de particule et utilisations de celles-ci
ES2351756B1 (es) * 2009-07-28 2011-10-05 Universidad Del Pais Vasco Nanopartículas lipídicas para terapia génica.
ES2385080B1 (es) * 2010-12-21 2013-05-10 Universidad Del Pais Vasco-Euskal Herriko Unibertsitatea Nanopartículas lipídicas para el tratamiento de enfermedades oculares.
EP2841098A4 (fr) 2012-04-23 2016-03-02 Allertein Therapeutics Llc Nanoparticules pour le traitement d'allergies
JP2016516754A (ja) 2013-04-03 2016-06-09 アラーテイン・セラピューティクス・リミテッド・ライアビリティ・カンパニーＡｌｌｅｒｔｅｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， ＬＬＣ 新規のナノ粒子組成物
EP3160449B1 (fr) 2014-06-24 2023-12-13 The Trustees of Princeton University Procédé d'encapsulation de composés biologiques, thérapeutiques et agents d'imagerie solubles
WO2017112828A1 (fr) * 2015-12-22 2017-06-29 The Trustees Of Princeton University Procédé d'encapsulation de composés biologiques, thérapeutiques et d'agents d'imagerie solubles
KR102487144B1 (ko) 2016-11-21 2023-01-12 에이리온 테라퓨틱스, 인코포레이티드 큰 물질의 경피 전달
WO2019055539A1 (fr) 2017-09-12 2019-03-21 Prudhomme Robert K Nanoparticules de polymère cellulosique et leurs procédés de formation
EP3703667A4 (fr) 2017-11-03 2021-08-04 The Trustees of Princeton University Appariement d'ions hydrophobes et nanoprécipitation flash pour la formation de formulations de nanovecteurs à libération contrôlée
US12186436B2 (en) 2018-07-19 2025-01-07 The Trustees Of Princeton University Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents
US11731099B2 (en) 2018-07-20 2023-08-22 The Trustees Of Princeton University Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation
US20200147032A1 (en) 2018-11-14 2020-05-14 Robert K. Prud'homme Dihydromyricetin hot melt extrusion formulations and methods for forming them
AU2022405521A1 (en) 2021-12-08 2024-05-09 Immunitybio, Inc. Neoepitope vaccine delivery vehicle and methods of making the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5539294A (en) * 1992-12-24 1994-07-19 Hemagen/Pfc Fluorocarbon emulsions
US5733526A (en) * 1995-12-14 1998-03-31 Alliance Pharmaceutical Corp. Hydrocarbon oil/fluorochemical preparations and methods of use

Also Published As

Publication number Publication date
EP1379227A4 (fr) 2007-12-12
WO2002076441A1 (fr) 2002-10-03
EP1379227A1 (fr) 2004-01-14

Similar Documents

Publication Publication Date Title
CA2445125A1 (fr) Micro-emulsions en tant que precurseurs de nanoparticules solides
US7153525B1 (en) Microemulsions as precursors to solid nanoparticles
Colley et al. Polymersome-mediated delivery of combination anticancer therapy to head and neck cancer cells: 2D and 3D in vitro evaluation
Saravanan et al. Nano-medicine as a newly emerging approach to combat human immunodeficiency virus (HIV)
Shah et al. The impact of size on particulate vaccine adjuvants
Cui et al. Genetic immunization using nanoparticles engineered from microemulsion precursors
EP4126021A1 (fr) Compositions et procédés pour l'administration d'arn
Garg et al. Colloidal drug delivery systems: current status and future directions
Pathak et al. Application of nanoemulsions in drug delivery
Maddiboyina et al. Perspectives on cutting‐edge nanoparticulate drug delivery technologies based on lipids and their applications
Mumper et al. Nanotemplate engineering of cell specific nanoparticles
Monroe et al. Harnessing nanostructured systems for improved treatment and prevention of HIV disease
Atre et al. A brief overview of quality by design approach for developing pharmaceutical liposomes as nano-sized parenteral drug delivery systems
Hanumanaik et al. Solid lipid nanoparticles: a review
Patil et al. Subunit microparticulate vaccine delivery using microneedles trigger significant SARS-spike-specific humoral and cellular responses in a preclinical murine model
Toudeshkchouei et al. Recent approaches to mRNA vaccine delivery by lipid-based vectors prepared by continuous-flow microfluidic devices
EP4442256A1 (fr) Compositions de nanoparticules lipidiques
Gupta et al. Lipid nanoformulations for oral delivery of bioactives: an overview
del Pozo-Rodríguez et al. Lipid nanoparticles as vehicles for macromolecules: nucleic acids and peptides
Patel et al. Lipid-based drug delivery system: spotlight on nanoemulsion as versatile nanocarrier
US20190328903A1 (en) Polymer nanoparticle composition for plasmid dna delivery, and preparation method therefor
Popli et al. Polymeric and lipidic nanoparticles in transforming anti-HIV combinational therapy: can they turn the tide?
Elkateb Design of Lipid-Based Nanocarriers for the Treatment of Human Immunodeficiency Virus (HIV)
Beg et al. Nanomedicine for the treatment of disease: from concept to application
Schiller Scalable processes to manufacture nanoparticulate dosage forms for oral vaccination

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead